Antimicrobial resistance (AMR) represents a serious and growing threat to human health worldwide. It already kills 700 000 people globally every year, and that number could increase to 10 million by 2050. To combat AMR EU launched a new programme ND4BB, which features an unprecedented partnership between industry and academia, and it is supported by public and private funding. To boost early stage of antibiotic discovery (which is the most difficult stage), a new platform ENABLE was created with ND4BB program.
As a member of ENABLE consortium, we are involved in the development and optimization of molecules with the potential to become future antibacterial drug candidates.
44. Optimized Synthesis of Indole Carboxylate Metallo-β-Lactamase Inhibitor EBL-3183
41. Synthesis, Antibacterial and Antiribosomal Activity of the 3C-Aminoalkyl Modification in the Ribofuranosyl Ring of Apralogs (5-O-Ribofuranosyl Apramycins)
38. Imitation of β-lactam binding enables broad-spectrum metallo-β-lactamase inhibitors
35. Synthesis and Antibacterial Activity of Propylamycin Derivatives Functionalized at the 5′′- and Other Positions with a View to Overcoming Resistance Due to Aminoglycoside Modifying Enzymes
31. Structure-activity relationship studies on the inhibition of the bacterial translation of novel Odilorhabdins analogues
24. Mechanistic aspects of maltotriose-conjugate translocation to the Gram-negative bacteria cytoplasm
Dumont, E.; Vergalli, J.; Pajovic, J.; Bhamidimarri, S. P.; Morante, K.; Wang, J.; Lubriks, D.; Suna, E.; Stavenger, R. A.; Winterhalter, M.; Refregiers, M.; Pages, J. M. Life Science Alliance 2019, 2, e201800242.